TY  - JOUR
AU  - Jovanović, Dragana
AU  - Roksandić-Milenković, Marina
AU  - Kotur-Stevuljević, Jelena
AU  - Ceriman, Vesna
AU  - Vukanić, Ivana
AU  - Samardžić, Natalija
AU  - Popević, Spasoje
AU  - Ilić, Branislav
AU  - Gajić, Milija
AU  - Simon, Marioara
AU  - Simon, Ioan
AU  - Spasojević-Kalimanovska, Vesna
AU  - Belić, Milica
AU  - Mirkov, Damjan
AU  - Šumarac, Zorica
AU  - Milenković, Vladislav
PY  - 2019
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3341
AB  - Background: The objective of this prospective study was to evaluate whether soluble programmed cell death-1/programmed cell death-ligand 1 (PD-1/PD-L1) and serum amyloid A1 (SAA1) are potential diagnostic, predictive or prognostic biomarkers in lung cancer. Methods: Lung cancer patients (n=115) with advanced metastatic disease, 101 with non-small cell lung cancer, NSCLC (77 EGFR wild-type NSCLC patients on chemotherapy, 15 EGFR mutation positive adenocarcinoma patients, 9 patients with mPD-L1 Expression >= 50% NSCLC - responders to immunotherapy), and 14 patients with small cell lung cancer (SCLC) were examined. ELISA method was used to determine sPD-L1 and SAA1 concentrations in patients' plasma. Results: Significantly higher blood concentrations of sPD-L1 and SAA1 were noted in lung cancer patients compared with a healthy control group. In PD-L1 + NSCLC patients, a significantly higher sPD-L1 level was noticed compared to any other lung cancer subgroup, as well as the highest average SAA1 value compared to other subgroups. Conclusions: It seems that sPD-1/PD-L1 might be a potential biomarker, prognostic and/or predictive, particularly in patients treated with immunotherapy. Serum amyloid A1 has potential to act as a good predictor of patients' survival, as well as a biomarker of a more advanced disease, with possibly good capability to predict the course of disease measured at different time points.
PB  - Društvo medicinskih biohemičara Srbije, Beograd i Versita
T2  - Journal of Medical Biochemistry
T1  - Soluble sPD-L1 and serum amyloid A1 as potential biomarkers for lung cancer
VL  - 38
IS  - 3
SP  - 332
EP  - 341
DO  - 10.2478/jomb-2018-0036
ER  - 

@article{
author = "Jovanović, Dragana and Roksandić-Milenković, Marina and Kotur-Stevuljević, Jelena and Ceriman, Vesna and Vukanić, Ivana and Samardžić, Natalija and Popević, Spasoje and Ilić, Branislav and Gajić, Milija and Simon, Marioara and Simon, Ioan and Spasojević-Kalimanovska, Vesna and Belić, Milica and Mirkov, Damjan and Šumarac, Zorica and Milenković, Vladislav",
year = "2019",
abstract = "Background: The objective of this prospective study was to evaluate whether soluble programmed cell death-1/programmed cell death-ligand 1 (PD-1/PD-L1) and serum amyloid A1 (SAA1) are potential diagnostic, predictive or prognostic biomarkers in lung cancer. Methods: Lung cancer patients (n=115) with advanced metastatic disease, 101 with non-small cell lung cancer, NSCLC (77 EGFR wild-type NSCLC patients on chemotherapy, 15 EGFR mutation positive adenocarcinoma patients, 9 patients with mPD-L1 Expression >= 50% NSCLC - responders to immunotherapy), and 14 patients with small cell lung cancer (SCLC) were examined. ELISA method was used to determine sPD-L1 and SAA1 concentrations in patients' plasma. Results: Significantly higher blood concentrations of sPD-L1 and SAA1 were noted in lung cancer patients compared with a healthy control group. In PD-L1 + NSCLC patients, a significantly higher sPD-L1 level was noticed compared to any other lung cancer subgroup, as well as the highest average SAA1 value compared to other subgroups. Conclusions: It seems that sPD-1/PD-L1 might be a potential biomarker, prognostic and/or predictive, particularly in patients treated with immunotherapy. Serum amyloid A1 has potential to act as a good predictor of patients' survival, as well as a biomarker of a more advanced disease, with possibly good capability to predict the course of disease measured at different time points.",
publisher = "Društvo medicinskih biohemičara Srbije, Beograd i Versita",
journal = "Journal of Medical Biochemistry",
title = "Soluble sPD-L1 and serum amyloid A1 as potential biomarkers for lung cancer",
volume = "38",
number = "3",
pages = "332-341",
doi = "10.2478/jomb-2018-0036"
}

Jovanović, D., Roksandić-Milenković, M., Kotur-Stevuljević, J., Ceriman, V., Vukanić, I., Samardžić, N., Popević, S., Ilić, B., Gajić, M., Simon, M., Simon, I., Spasojević-Kalimanovska, V., Belić, M., Mirkov, D., Šumarac, Z.,& Milenković, V.. (2019). Soluble sPD-L1 and serum amyloid A1 as potential biomarkers for lung cancer. in Journal of Medical Biochemistry
Društvo medicinskih biohemičara Srbije, Beograd i Versita., 38(3), 332-341.
https://doi.org/10.2478/jomb-2018-0036

Jovanović D, Roksandić-Milenković M, Kotur-Stevuljević J, Ceriman V, Vukanić I, Samardžić N, Popević S, Ilić B, Gajić M, Simon M, Simon I, Spasojević-Kalimanovska V, Belić M, Mirkov D, Šumarac Z, Milenković V. Soluble sPD-L1 and serum amyloid A1 as potential biomarkers for lung cancer. in Journal of Medical Biochemistry. 2019;38(3):332-341.
doi:10.2478/jomb-2018-0036 .

Jovanović, Dragana, Roksandić-Milenković, Marina, Kotur-Stevuljević, Jelena, Ceriman, Vesna, Vukanić, Ivana, Samardžić, Natalija, Popević, Spasoje, Ilić, Branislav, Gajić, Milija, Simon, Marioara, Simon, Ioan, Spasojević-Kalimanovska, Vesna, Belić, Milica, Mirkov, Damjan, Šumarac, Zorica, Milenković, Vladislav, "Soluble sPD-L1 and serum amyloid A1 as potential biomarkers for lung cancer" in Journal of Medical Biochemistry, 38, no. 3 (2019):332-341,
https://doi.org/10.2478/jomb-2018-0036 . .